Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$994.9M
87M shares
52-week range
$4.12 – $36.26
25% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.41%
Easy to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $8.2K | $9.0K | $11.0K | $0 | $0 | $0 | $0 | $0 |
| Gross profit | −$8.2K | −$9.0K | −$11.0K | $0 | $0 | $0 | $0 | $0 |
| Gross margin | — | — | — | — | — | — | — | — |
| R&D | $1.7M | $3.9M | $13.7M | $51.1M | $82.3M | $86.1M | $124.5M | $157.7M |
| Operating income | −$2.1M | −$4.3M | −$21.5M | −$71.5M | −$107.0M | −$105.0M | −$142.3M | −$178.7M |
| EBITDA | −$2.1M | −$4.3M | −$21.5M | −$70.9M | −$104.4M | −$96.3M | −$129.1M | −$162.0M |
| Net income | −$2.2M | −$4.3M | −$22.1M | −$71.1M | −$104.8M | −$96.7M | −$129.5M | −$162.5M |
| Net margin | — | — | — | — | — | — | — | — |
| EPS (diluted) | -0.16 | -0.11 | -0.58 | -1.79 | -2.62 | -2.14 | -2.20 | -1.87 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $2M | $-2.22 | $-2.32–$-2.15 | 7 |
| 2027 | $23M | $-2.45 | $-2.81–$-2.28 | 7 |
| 2028 | $132M | $-1.85 | $-2.79–$-1.00 | 4 |
| 2029 | $295M | $-1.09 | $-1.83–$-0.45 | 2 |
Forward consensus · source: Financial Modeling Prep
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.
www.olema.comNo one on the platform currently holds OLMA.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-12-31 | 25,067 | $626.7K |
No one on the platform has traded OLMA yet.
| $37M |
| — |
| KALVKalVista Pharmaceuticals, Inc. | $27.00 | +0.00% | $1.4B | — |
| LXRXLexicon Pharmaceuticals, Inc. | $2.53 | -0.70% | $1.1B | — |
Source: Financial Modeling Prep · peers by sector/industry
$OLMA Could a new 52 week high could be in our near future? Maybe just one positive announcement away.
View on StockTwits ↗$OLMA Early-stage data for palazestrant has shown promising clinical benefits in heavily pre-treated estrogen-receptor-positive (ER+) breast cancer, giving it a different therapeutic baseline than Roche's drug.
View on StockTwits ↗$OLMA Olema's palazestrant has demonstrated preclinical properties that suggest it might be a more potent degrader of estrogen receptors, with the potential to work where other selective estrogen receptor degraders (SERDs) fall short.
View on StockTwits ↗$OLMA oh fam! We have done it once again. Another 20%+ 🚀 ripper within just days memorialized into the stocktwits records. Some call it luck, 7000 times is luck? Some say anyone can do this. Fine, show us. I want to follow someone.
View on StockTwits ↗$OLMA come on, a little more 🚀 juice for that 20% ripper within hours
View on StockTwits ↗$OLMA look at that, another 14%+ 🚀 ripper within just days memorialized into the stocktits records. #6703
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.